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Kaposi’s Sarcoma-Associated Herpesvirus-Encoded Viral IRF3
Modulates Major Histocompatibility Complex Class II (MHC-II)
Antigen Presentation through MHC-II Transactivator-Dependent
and -Independent Mechanisms: Implications for Oncogenesis
Jianmin Zuo,a Andrew D. Hislop,a Carol S. Leung,b Shereen Sabbah,c Martin Rowea
Cancer Research UK Birmingham Cancer Centre, University of Birmingham, Birmingham, United Kingdoma; Department of Viral Immunobiology, Institute of Experimental
Immunology, University of Zürich, Zürich, Switzerlandb; Department of Immunobiology, King’s College London, London United Kingdomc
Evasion of immune T cell responses is crucial for persistent viruses to establish a normal carrier state. Most studies on active im-
mune modulation mechanisms have focused on the stage of virus production in infected cells, when large numbers of viral anti-
gens and potential immune modulators are expressed. For oncogenic viruses such as Kaposi’s sarcoma-associated herpesvirus
(KSHV), which is carried as a lifelong infection, usually with little harmful effect, but can cause various tumors, the immune eva-
sion strategies can also be relevant in the context of tumorigenesis. Here we report that the virus-encoded interferon regulatory
factor 3 (vIRF3) latent viral gene expressed in KSHV-related tumors functions as a potent immunevasin. Expression of vIRF3
downregulates surface major histocompatibility complex class II (MHC-II) DR expression with slow kinetics but, more impor-
tantly, can substantially inhibit recognition by KSHV-specific CD4 T cells prior to its effects on MHC-II DR downregulation in
model cell systems. This property of vIRF3 is only partly due to its ability to inhibit the transcription of CIITA and, thus,
MHC-II expression; CIITA-independent inhibition of MHC-II transcripts and another as yet unidentified posttranscriptional
mechanism are also involved in qualitatively modulating the availability of specific peptide/MHC-II complexes at the cell sur-
face. Consistent with these observations, the vIRF3-expressing KSHV-associated primary effusion lymphoma (PEL) lines are
generally resistant to recognition by KSHV-specific CD4 T cells. Interestingly, some PEL lines exhibit small subpopulations with
lower vIRF3 expression that can be recognized. These data implicate vIRF3 as a critical determinant of the MHC-II antigen pre-
sentation function in KSHV-associated PELs that is likely to be important in the pathogenesis of these tumors.
Infection with Kaposi’s sarcoma-associated herpesvirus (KSHV)results in a lifelong carriage state, usually with little harmful
effect. However, the virus can cause Kaposi’s sarcoma, an AIDS-
associated malignancy, and has been proposed to be the etiological
agent of primary effusion lymphoma (PEL) and multicentric
Castleman’s disease (MCD) (1–4). KSHV can establish latent in-
fections in the B cell compartment and has the potential to trans-
form cell growth (5), a property that is relevant to its mechanisms
of persistence in immunocompetent hosts as well as its oncogenic
potential.
Successful persistence of viral infection depends on the estab-
lishment of a balance between host immune responses and viral
immune evasion. The innate immune system provides an imme-
diate defense against infection and is very important for control-
ling viral infections. Remarkably, KSHV encodes four proteins
named virus-encoded interferon regulatory factors (vIRFs) that
are homologues of cellular IRFs. The vIRFs have been shown to
inhibit IFN responses (6). With regard to adaptive immune re-
sponses, KSHV genes reported to modulate major histocompati-
bility complex class I (MHC-I) antigen presentation include K3
and K5 (7, 8). However, KSHV is poorly understood in terms of its
interference with the MHC-II antigen presentation pathway.
Mechanisms for interfering with the MHC-II antigen presen-
tation pathway have been reported for other herpesviruses and
involve multiple points on the MHC class II antigen presentation
pathway (9). For example, US2 (10), US3 (11), and pp65 (12) of
human cytomegalovirus (HCMV) and glycoprotein B of human
herpes simplex virus 1 (13) all target the HLA-DR molecule for
diversion and/or degradation during membrane transport. More
recently, Epstein-Barr virus (EBV)-encoded BZLF1 has been
shown to target CD74, the invariant-chain chaperone of HLA-
DR, to evade CD4 T cell recognition (14). The gp42 protein of
EBV also binds to MHC-II to sterically inhibit CD4 T cell receptor
interactions (15).
Using peripheral blood mononuclear cells from healthy
KSHV-infected donors, Sabbah et al. successfully identified and
isolated CD4 T cell responses to LANA, a protein expressed in all
KSHV-infected cells, whether normal or malignant. However,
most PEL cell lines were not be able to be recognized by these CD4
T cell clones, except via reexpression of the MHC class II transac-
tivator (CIITA) in the PELs (16). A study from another group
showed that vIRF3 can inhibit the PIII and PIV promoters of
CIITA and can inhibit the transcription and translation of
MHC-II elements (17), which provides a potential explanation for
the poor recognition of PELs by the LANA-specific CD4 T cells.
However, the small MHC-II downregulation observed in the lat-
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ter study cannot fully explain the substantially reduced MHC-II
expression observed in the PELs. There is also no direct evidence
that this inhibition of transcription of CIITA by vIRF3 can impair
the recognition by CD4 T cells.
In the study described here, we have carried out a more detailed
analysis of the effects of vIRF3 on MHC-II antigen presentation
and, importantly, have extended the work to include functional T
cell recognition assays as a readout. We demonstrate for the first
time that vIRF3 does indeed impair the recognition by KSHV-
specific CD4 T cells in B cells and PEL lines and that the ability of
PEL cells to be recognized by LANA-specific CD4 T cells corre-
lated with vIRF3 expression at the single-cell level. Using quanti-
tative reverse transcription-PCR (RT-PCR), we demonstrate that
vIRF3 can inhibit the transcription of CIITA and MHC-II ele-
ments, through which vIRF3 can substantially downregulate
MHC-II expression, but with slow kinetics that lag behind an ef-
fect on functional presentation of antigen to CD4 T cells. The data
reveal additional mechanisms of impairment of MHC-II antigen
presentation by vIRF3 which are partly mediated through a
CTIIA-independent inhibition of the transcription of MHC-II el-
ements.
MATERIALS AND METHODS
Plasmids and transfection. The vIRF3 gene was subcloned into the
EcoRI/XhoI sites of the pCDNA3-IRES-nls-GFP plasmid vector and was
verified by restriction digestion and sequence analysis. The pCDNA3-
cyto-EBNA1 plasmid was kindly provided by Graham Taylor (18). The
Mel JuSol (MJS) melanoma-derived cell line (19) was maintained in
RPMI 1640 medium (Gibco BRL) supplemented with 10% fetal calf se-
rum (FCS). Transient transfection of MJS cells with plasmid DNA was
routinely performed using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. Targets for the T cell recognition assay
clone were generated by cotransfection of HLA-DRB51 MJS cells (14)
with the cyto-EBNA1, empty-IRES-GFP, or vIRF3-IRES-GFP expression
plasmid.
Retrovirus and transduction. Retroviral constructs were engineered
by cloning vIRF3 or HLA-B81 as a control into the pLZRS retroviral
vector. Immediately downstream from the inserted gene was an internal
ribosome entry site (IRES) and the marker gene, either truncated nerve
growth factor (NGFR) or green fluorescent protein (GFP). Vesicular
stomatitis virus-pseudotyped retrovirus particles were produced in GP2-
293 cells cotransfected with the pVSV-G envelope vector. Virus in the
culture supernatant at 72 h was concentrated by ultracentrifugation (15
ml) and used to infect 5 105 target cells overnight. Lymphoblastoid cell
lines (LCLs) were established from healthy donor B cells using the B95.8
strain of EBV. Both LCLs and PELs were maintained in RPMI 1640 me-
dium (Gibco BRL) supplemented with 10% FCS. For the retrovirus that
coexpresses NGFR, the transduced LCL or PEL cells were magnetically
sorted using magnetically activated cell sorting NGFR-specific beads as
directed by the manufacturer (Miltenyi Biotech).
Stable transfection and establishment of pvIRF3-tet cell lines. A de-
rivative of the doxycycline (DOX)-dependent expression vector pRTS-1
(20) was kindly provided by J. Mautner, Munich, Germany; vIRF3 or the
reverse vIRF3 sequence as a control was introduced into the vector by
standard DNA cloning procedures to create vectors pRTS-CD2-vIRF3
and pRTS-CD2-control, respectively. The pRTS-CD2-vIRF3 or pRTS-
CD2-control vector was introduced into an EBV-negative derivative of
the Akata BL line, Akata-A3, by electroporation of 10 g plasmid DNA
into 107 cells in Opti-MEM medium (Invitrogen) at 280 V and 960 F
using a Bio-Rad electroporation apparatus. Transfected cells were cul-
tured in RPMI 1640 medium supplemented with 10% FCS. After 24 h, the
transfected cell population was enriched by staining with OX34 antibody
to rat CD2 and positively selected by magnetic cell sorting with anti-
mouse IgG2a/b microbeads and LS columns (Miltenyi Biotech) according
to the manufacturer’s guidelines. Cells were thereafter expanded and
maintained in RPMI 1640 medium supplemented with 10% FCS. Expres-
sion of vIRF3 was induced by addition of titrated doses of DOX, and the
induced cells were positively selected by magnetic cell sorting with anti-
NGFR microbeads and LS columns (Miltenyi Biotech). The purity of the
sorted cells was checked by flow cytometry.
Flow cytometry analysis of cell surface MHC molecules. Cell surface
expression of MHC-II DR or NGFR on viable cells was determined by
staining with phycoerythrin (PE)-conjugated anti-DR (Biolegend) or fluo-
rescein isothiocyanate (FITC)-conjugated anti-NGFR (Biolegend). Cell
surface expression of MHC-II DQ on viable cells was determined by stain-
ing with anti-DQ (Biolegend), followed by allophycocyanin (APC)-con-
jugated anti-mouse IgG (Biolegend). Stained cells were analyzed on a BD
Accuri C6 flow cytometer, and the data were processed using FlowJo
software (Tree Star).
Western blotting. Goat antibodies to calregulin, mouse anti-DR,
mouse anti-DR, mouse anti-DM, rat anti-LANA-1, and rabbit anti-
CIITA were purchased from Santa Cruz Biotechnology. Mouse anti-
KSHV-encoded vIRF3 was purchased from Novus Biologicals. Total cell
lysates were denatured in reducing sample buffer (final concentrations,
2% sodium dodecyl sulfate [SDS], 72.5 mM Tris-HCl, pH 6.8, 10% glyc-
erol, 0.2 M sodium 2-mercaptoethane-sulfonate, 0.002% bromophenol
blue) and then sonicated and heated to 100°C for 5 min. Solubilized pro-
teins equivalent to 105 cells/20-l sample were separated by SDS-poly-
acrylamide gel electrophoresis (PAGE) on 4 to 12% acrylamide gradient
bis-Tris NuPage minigels with MOPS (morpholinepropanesulfonic acid)
running buffer (Invitrogen). Following electroblotting to polyvinylidene
difluoride membranes, immunoblotting with specific primary antibodies
followed by detection with appropriate alkaline phosphatase-conjugated
secondary antibodies and a CDP-Star chemiluminescence detection kit
(Tropix; Applied Biosystems) was performed as previously described
(21).
T cell function assays. T cells were grown in 10% FCS in RPMI 1640
medium supplemented with 30% supernatant from the interleukin-2 (IL-
2)-producing MLA-144 cell line and 50 U/ml recombinant IL-2. The ef-
fector CD4T cell clones SNP (specific for amino acids 474 to 493 of EBV
EBNA1 and restricted through DRB51), LAP/LRS (specific for amino ac-
ids 191 to 210 of KSHV LANA1 and restricted through DQ6), and LAP
(specific for amino acids 191 to 205 of KSHV LANA1 and restricted
through DP1) were generated as described elsewhere (16, 18). The effector
CD8 T cell clone CLG (specific for amino acids 426 to 434 of LMP2 and
restricted through MHC-I A0201) was described elsewhere (22). The ca-
pacity of CD4 and CD8 T cell clones to recognize target LCLs, MJS
cells, or BCBL-1 cells was measured by a gamma interferon (IFN-)-
specific enzyme-linked immunosorbent assay (ELISA). Briefly, 104 effec-
tor T cells were incubated for 18 h at 37°C in V-bottom microtest plate
wells with 105 target cells, before assaying the supernatants for IFN-
release by ELISA (Endogen) in accordance with the manufacturer’s rec-
ommended protocol. Antigen-sensitized targets were either incubated
with peptides for 1 h or cultured for 18 h with LANA protein preparations
(16) in AIM-V medium (Invitrogen).
QRT-PCR assay. Total RNA was isolated from cultured cell lines using
a Qiagen RNeasy kit and treated with DNase I (Turbo DNA-free kit;
Ambion). Quantitative RT-PCR (QRT-PCR) assays for CIITA, DRA,
DRB, DQA, DPA, DMA, DOA, CD74, HLA-A, and PGK were performed
with TaqMan gene expression assays (Applied Biosystems), duplexed
with GAPDH (glyceraldehyde-3-phosphate dehydrogenase) assays for
normalization.
RESULTS
vIRF3 expression level is related to MHC-II antigen presenta-
tion in PELs. In a previous paper (16), we speculated that the poor
recognition of PELs by MHC-II-matched LANA-specific CD4 T
cells was due to the expression of vIRF3. On closer examination of
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the VG-1 PEL line (23), we observed normal levels of MHC class II
cell surface receptor (both MHC-II DR and MHC-II DQ) expres-
sion in a small subpopulation of cells (high DR DQ population)
(Fig. 1A). Flow cytometry cell sorting of MHC-II DR-stained
VG-1 cells enabled the isolation of two populations: one with high
DR expression and the other with low DR expression (Fig. 1B).
These two populations of VG-1 cells were assayed for recognition
by MHC-II-matched LANA-specific CD4 T cells restricted
through DQ6 (LAP/LRS peptide specific) or DP1 (LAP peptide
specific) (16). Recognition was measured from the release of
FIG 1 vIRF3 expression level is related to MHC-II antigen presentation in PELs. (A) To measure surface MHC-II DR and DQ expression, VG-1 cells were stained
with anti-DQ, followed by APC-conjugated anti-mouse IgG and then PE-conjugated anti-DR. The cells were analyzed by flow cytometry and displayed as a dot
plot of APC-conjugated DQ versus PE-conjugated DR fluorescence. (B) To purify the high-DR-expressing VG-1 cells stained with PE-conjugated anti-DR, cells
were analyzed on a Mo-Flow cell sorter and the weakest DR-expressing cells and the strongest DR-expressing cells were gated (left, showing a dot plot of side
scatter [SS] versus PE fluorescence) and sorted. (Right) Analysis of cell populations sorted for high DR expression (dashed line) and low DR expression (solid
line). (C) Sensitivity of sorted VG-1 cells with high DR and low DR expression (black bars, 1 105 cells; gray bars, 2 104 cells) to LAP/LRS or LAP CD4 effector
T cells (both specific for LANA-derived peptide). Target and effector cells were cocultured for 18 h before assaying for T cell recognition by IFN--specific ELISA.
The DQ6- and DP1-positive LCLs pulsed with peptides (pep) served as positive-control targets. Error bars for IFN- release in the histograms indicate the
standard deviations of triplicate cultures. (D) Sorted VG-1 cells with high DR and low DR expression were analyzed by SDS-PAGE and immunoblotting with
antibodies specific for vIRF3, LANA, or calregulin as a loading control. The blot is from one representative experiment. The histogram shows the mean 
standard deviation of 3 independent replicate experiments quantified by densitometry, where the densities of the vIRF3 or LANA bands were normalized relative
to the density of their own calregulin loading control.
Zuo et al.
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IFN- from the effector T cells. Little or no recognition of VG-1
cells with low DR expression was observed, but there was clear
recognition of VG-1 cells with high DR expression that was in
some cases comparable to the recognition of control B cells pulsed
with synthetic target peptide (Fig. 1C). Aliquots of cells from rep-
licate experiments were analyzed by immunoblotting, and band
intensities were quantified. The mean expression of vIRF3 expres-
sion in VG-1 cells with high DR expression compared with that in
VG-1 cells with low DR expression was 51.5% 6.3% (Fig. 1D).
Expression of LANA showed less of a reduction, with a mean
expression of 75.5%  3.4% in VG-1 cells with high DR expres-
sion compared with that for VG-1 cells with low DR expression.
Similar results were obtained with another PEL cell line, BC-1
(data not shown).
These data extend previously published results to provide
strong support for the idea that vIRF3 expression level is indeed
related to MHC-II antigen presentation in PELs.
vIRF3 can modulate MHC-II antigen presentation in MJS
cells. A potential mechanistic explanation for the inverse correla-
tion between vIRF3 and MHC-II antigen presentation in PELs
might be found in the recent demonstration that vIRF3 inhibits
the promoters of CIITA, leading to inhibition of the transcription
and translation of MHC-II elements (17). To investigate this pos-
sibility in more detail, we tested the effect of vIRF3 on MHC-II
antigen presentation using CD4 T cell effectors in a functional
assay previously developed in our Birmingham laboratories (14).
MJS melanoma cells expressing MHC-II DRB51 were transfected
with a cyto-EBNA1 expression plasmid together with an empty
IRES-GFP vector or with a vIRF3-IRES-GFP vector expressing
vIRF3. The cultures were then cocultured with MHC-II DRB51-
restricted CD4 T cells specific for the SNP EBNA1-derived pep-
tide, and T cell recognition was measured from the release of
IFN- from the effector cells. Mock-transfected cells were not
recognized, but good recognition was seen with target cells
cotransfected with cyto-EBNA1 and the control IRES-GFP vector
(Fig. 2A). A substantial 50% reduction in recognition of cyto-
EBNA1 was observed when the target cells were cotransfected with
vIRF3 (Fig. 2A).
Replicate aliquots of cells analyzed by immunoblotting con-
firmed expression of vIRF3 in the cultures transfected with the
vIRF3-GFP plasmid, in which about 10% of the cells became GFP
positive (GFP), and the levels of EBNA1 were similar between
the cells cotransfected with cyto-EBNA1 and IRES-GFP or vIRF3-
GFP (Fig. 2B). Two-color flow cytometry analysis of viable cells
stained for surface MHC-II DR suggested that vIRF3 caused a
small but reproducible reduction (about 15%) in the level of cell
surface DR molecules on GFP cells compared to the expression
on untransfected GFP-negative (GFP	) cells in the same cultures
(Fig. 2C). In four independent experiments, the mean expression
of surface MHC-II DR in the GFP cells compared to untrans-
fected GFP	 cells was 85.8% 7.5% (P
 0.0089).
vIRF3 can inhibit CIITA transcription and reduce surface
MHC-II DR expression, but with slow kinetics. The key finding
from the transient-transfection experiments whose results are
shown in Fig. 2 was that a substantial reduction of CD4 T cell
recognition was observed with only a very small reduction of cell
surface MHC-II DR expression. As vIRF3 is a latent gene that is
constitutively expressed in KSHV-positive PELs (24, 25), it is
physiologically relevant to also check the phenotype of vIRF3 at
later time points. To this end, we generated a bicistronic retrovi-
rus, pLZRS-vIRF3-IRES-NGFR, that coexpresses vIRF3 with a
truncated inactive NGFR, which was used as a marker to identify
and purify the transduced population. The MJS cells were trans-
duced with control, LZRS-B81-IRES-NGFR, or LZRS-vIRF3-
IRES-NGFR retroviruses, and surface MHC-II expression was
monitored through two-color flow cytometry staining of surface
MHC-II DR and NGFR as a surrogate marker of vIRF3 expression
(Fig. 3A). At day 2, the relative fluorescence intensity of surface
DR staining on the NGFR-positive (NGFR) (vIRF3-positive
[vIRF3]) cells was about 60% compared to that of untransduced
NGFGR-negative (NGFR	) (vIRF3-negative [vIRF3	]) cells in
the same culture (Fig. 3A, left). However, by day 5, the surface DR
expression was substantially reduced to about 13% by vIRF3 (Fig. 3A,
middle), and at day 7, the surface DR expression was reduced to about
7% on NGFR (vIRF3) cells compared to the expression on un-
transduced NGFR	 (vIRF3	) cells (Fig. 3A right, and B).
To enable analysis of MHC-II locus transcripts and protein,
FIG 2 vIRF3 can modulate MHC-II antigen presentation in MJS cells.
DRB51-expressing MJS cells were cotransfected with the pCDNA-cyto-
EBNA1 expression vector together with IRES-GFP (GFP) or vIRF3-GFP
(vIRF3) expression plasmids. (A) At 24 h posttransfection, the cells were
used as targets for SNP CD4 effector T cells (specific for an EBNA1-
derived peptide) for a further 18 h before assaying for T cell recognition by
IFN--specific ELISA. The DRB51-expressing MJS cells pulsed with pep-
tides served as controls. Error bars for the IFN- release in the histograms
indicate the standard deviations of triplicate cultures. (B) Total cell lysates
of target cells were analyzed by immunoblotting using antibodies specific
for EBNA1, vIRF3, DR, or calregulin as a loading control. A nonspecific
(ns) band on the blot is indicated. (C) Viable transfected target cells were
stained with PE-conjugated anti-DR and analyzed by flow cytometry. His-
tograms show the surface MHC-II DR expression on GFP	 cells and GFP
cells.
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the control retrovirus- and vIRF3 retrovirus-transduced cells in
these experiments were purified by NGFR sorting at each time
point after transduction. QRT-PCR assays with total mRNA iso-
lated from these samples showed that vIRF3 can effectively inhibit
the transcription of CIITA and MHC-II elements DR and DP as
early as 2 days after transduction (Fig. 3C and D). More extensive
transcriptional analyses on the day 7 samples showed that the
transcripts of CIITA and all MHC-II elements tested (including
DRA, DRB, DPA, DMA, DOA, and CD74) were significantly
downregulated following vIRF3 expression in MJS cells (P 0.01)
(Fig. 3D).
Immunoblot analysis of cell lysates at day 7 confirmed the ex-
pression of vIRF3 and a corresponding reduction in total cellular
DR protein expression in the cell lysates from vIRF3-transduced
cells compared to control retrovirus-transduced cells (Fig. 3E).
Together, these data show that vIRF3 can substantially reduce
total and surface MHC-II DR protein expression but that it does
so with much slower kinetics than the more immediate inhibition
of CIITA expression and subsequent impairment of MHC-II ele-
ment transcription.
Ectopic expression of CIITA can partly abolish surface
MHC-II DR downregulation by vIRF3. To investigate whether
the delayed substantial reduction of surface MHC-II DR protein
expression in MJS cells was due to the inhibition of CIITA tran-
scription, we generated an MJS cell line with ectopic overexpres-
sion of CIITA driven by a retrovirus promoter. It was confirmed
by immunoblotting that CIITA was overexpressed in the CIITA-
expressing MJS cell line, which resulted in a small increase of the
already high levels of MHC-II DR expression in MJS cells that was
evident by flow cytometry (Fig. 4A). In the next set of experi-
ments, MJS cells and CIITA-expressing MJS cells were transduced
with control/GFP or vIRF3/GFP bicistronic retroviruses to exam-
ine whether constitutive overexpression of CTIIA might affect the
ability of vIRF3 to downregulate surface MHC-II DR expression.
Expression of vIRF3 was confirmed by immunoblotting of cell
lysates (Fig. 4C). Flow cytometry revealed that when maximal in-
hibition of MHC-II DR expression by vIRF3 was achieved (i.e., by
day 9 in Fig. 4B), the level of surface DR on vIRF3/GFP-express-
ing control MJS cells was reduced to about 11% of the expression
in GFP	, non-vIRF3-expressing MJS cells, whereas in CIITA-ex-
pressing MJS cells, the expression of vIRF3 reduced the level of
surface DR expression to 28% of the level of expression in non-
vIRF3-expressing cells. Reproducibly, the constitutive overex-
pression of CTIIA in MJS cells resulted in about 3 times more
surface DR in vIRF3-expressing cells.
These data are consistent with the reduction of surface MHC-II
DR expression and modulation of MHC-II antigen presentation
by vIRF3 being partially due to the inhibition of the transcription
of CIITA and the fact that the delayed effect on protein expression
FIG 3 vIRF3 inhibits CIITA transcription and substantially downregulates
surface MHC-II DR expression with slow kinetics. MJS cells were transduced
with retrovirus pLZRS-vIRF3-IRES-NGFR or a control vector, pLZRS-B81-
IRES-NGFR. (A) Transduced MJS cells were harvested at the indicated time
points, stained with PE-conjugated anti-DR plus FITC-conjugated anti-
NGFR, and analyzed by flow cytometry to determine the levels of DR expres-
sion on transduced (NGFR) cells and nontransduced (NGFR	) cells in the
same cultures. (B) Histograms show the surface MHC-II DR expression on
NGFR	 cells and NGFR cells at day 7 after retrovirus transduction. (C) At
day 2 after transduction, the transduced cells from control and vIRF3-trans-
duced cultures were purified with anti-NGFR magnetic beads. Relative levels
of CIITA, DRA, and DPA transcripts in total RNA isolated from transduced
and sorted cells normalized to the levels of the GAPDH transcripts measured
were measured by QRT-PCR assay. The error bars represent the standard
deviations of triplicate reactions. (D) At day 7 after transduction, mRNA from
sorted cells was assayed by QRT-PCR for an extended panel of transcripts:
CIITA, DRA, DRB, DQA, DPA, DMA, DOA, CD74, HLA-A, and PGK. The
error bars represent the standard deviations of triplicate reactions. (E) Total
cell lysates of the purified NGFR populations from control and vIRF3-trans-
duced cultures were analyzed by SDS-PAGE alongside lysates from JSC-1 cells.
The samples were immunoblotted with antibodies specific for vIRF3, HLA-
DR, or calregulin as a loading control.
Zuo et al.
5344 jvi.asm.org Journal of Virology
 o
n
 Septem
ber 17, 2013 by University of Birm
ingham
http://jvi.asm.org/
D
ow
nloaded from
 
is due to the known long half-life of MHC-II molecules. However,
it is important to note that the reduction of surface MHC-II DR
expression cannot be fully reversed by the ectopic overexpression
of CIITA.
vIRF3 inhibits CIITA transcription in a B cell line. All the
work described above was carried out in the MJS cell model, but in
the context of PELs, it would be physiologically more relevant to
examine the behavior of vIRF3 in B cells. To this end, we generated
from the EBV-negative Akata-A3 Burkitt lymphoma line transfec-
tants with a DOX-inducible vIRF3-expressing vector, pRTS-CD2-
vIRF3. The vIRF3 gene and an NGFR-IRES-GFP sequence were
regulated by a bidirectional DOX-regulated promoter which al-
lows the purification of vIRF3-expressing cells following DOX
induction. By titrating the concentration of DOX, at 2 ng/ml we
achieved expression levels of vIRF3 that were similar to those in
PELs (Fig. 5A). As we know from the previous experiments in MJS
cells that vIRF3 affects MHC-II with slow kinetics, we harvested
the B cells at 7 to 11 days postinduction. Two-color flow cytom-
etry analysis of viable cells stained for surface MHC-II DR sug-
gested that vIRF3 reduced the level of cell surface DR molecules
only slightly but reproducibly by about 15% (Fig. 5B). Immuno-
blot analysis of purified GFP/NGFR cells confirmed the expres-
sion of vIRF3 in the cells containing the vIRF3 vector, but the
levels of DR, DR, DM, and the MHC-I heavy chain were not
noticeably altered by vIRF3 (Fig. 5C). Analysis of RNA by QRT-
PCR showed that the transcripts of CIITA and, with the exception
of MHC-II DMA, all of the MHC-II elements tested were substan-
tially reduced (P  0.01) following vIRF3 expression compared
with the levels in control Akata-A3 cells (Fig. 5D).
Therefore, physiological levels of vIRF3 do effectively inhibit
CIITA and MHC-II element transcription in B cells but do not
necessarily impact the levels of MHC-II protein molecules in these
cells in the time scale of this experiment.
vIRF3 can modulate MHC-II antigen presentation in LCLs.
The results in Fig. 5 led us to examine what might be the effect of
vIRF3 on functional T cell recognition in B cells. To this end, we
generated EBV-transformed B LCLs that stably express vIRF3
through transduction with the pLZRS-vIRF3-IRES-NGFR retro-
virus, followed by two rounds of sorting for NGFR-expressing
cells. Expression of vIRF3 in the vIRF3-expressing LCLs was con-
FIG 4 Ectopic expression of CIITA partly abolishes vIRF3-mediated downregulation of surface MHC-II DR. (A) MJS cells transduced with a control IRES-
NGFR retrovirus or with a CIITA-IRES-NGFR retrovirus. (Left) Cell lysates prepared from MJS and CIITA-expressing MJS cells were analyzed by immuno-
blotting using antibodies specific for CIITA, the DR chain, or calregulin as a loading control; (right) transduced cells were stained with PE-conjugated anti-DR
and then analyzed by flow cytometry. Solid-line histogram, MHC-II DR expression on MJS cells; dashed-line histogram, expression on CIITA-expressing MJS
cells; shaded histogram, isotype control staining. (B) MJS and CIITA-expressing MJS cells transduced with retrovirus pLZRS-vIRF3-IRES-GFP were harvested
at the indicated times over 9 days for staining with PE-conjugated anti-DR and analysis by flow cytometry. Histograms show the surface MHC-II DR expression
on GFP	 cells and GFP cells at each time point. The numbers at the top of the histogram boxes are the relative fluorescent intensity compare with that of the
nontransfected GFP	 population, which was equal to 100, and that of the isotype control, which was equal to 0. (C) MJS and CIITA-expressing MJS cells were
transduced with retrovirus pLZRS-vIRF3-IRES-GFP, and expression of vIRF3 at 9 days postinfection was confirmed by immunoblotting of cell lysates alongside
lysates from JSC-1 cells. Con, control.
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firmed by immunoblotting, although it was clear that the levels
were lower than those of vIRF3 expression in PELs (Fig. 6A). Also,
there was no obvious difference in total cellular and surface
MHC-II DR expression between the control LCLs and vIRF3-
expressing LCLs (Fig. 6A).
To investigate the effect of vIRF3 on MHC-II antigen presen-
tation, control LCLs and vIRF3-expressing LCLs were fed LANA
protein and then cocultured with MHC-II-matched-allele
(DQ6)-restricted LAP/LRS LANA-specific CD4 T cells. T cell rec-
ognition was measured from the release of IFN- from the effector
cells, and peptide-pulsed target cells served as controls. There was
no recognition of either type of LCL pulsed with control protein.
Good recognition was seen with both LCLs when fed with LANA
protein, but there was an approximately 50% reduction of T cell
recognition in the LANA-fed vIRF3-expressing LCLs compared
with that in control LCLs (Fig. 6B). Furthermore, this reduction
was not observed when the LCLs were pulsed with specific LANA
peptides. In additional control experiments, the recognition by
HLA-A0201-restricted CD8 T cells specific for the GLC peptide of
EBV LMP2 did not differ between the control and vIRF3-express-
ing LCLs (Fig. 6C).
vIRF3 modulates MHC-II antigen presentation in BCBL-1
cells independently of CIITA inhibition. In our previous study,
we observed that one unique PEL line, BCBL-1, can be recog-
nized by LANA-specific CD4 T cells and correlated with the
lowest level of vIRF3 expression (16). To investigate whether
overexpression of vIRF3 in this PEL can modulate MHC-II
antigen presentation, we transduced BCBL-1 cells with control
pLZRS-B81-IRES-NGFR retrovirus and pLZRS-vIRF3-IRES-
NGFR retrovirus. At 7 to 10 days postinduction, these cells
were analyzed in various assays. Two-color flow cytometry
analysis of viable cells stained for surface MHC-II DR showed
that vIRF3 reduced the level of cell surface MHC-II DR expres-
sion by about 50% on NGFR/vIRF3 cells compared to the
level of expression on NGFR/vIRF3	 cells in the same cultures
(Fig. 7A). Immunoblot analysis of pure populations of vIRF3-
expressing BCBL-1 cells confirmed the overexpression of
vIRF3 in the vIRF3-expressing BCBL-1 cells compared with the
level of expression in control BCBL-1 cells and a concomitant
small level of reduction of total MHC-II DR expression follow-
ing vIRF3 expression (Fig. 7B).
To investigate whether this downregulation of MHC-II DR
expression is sufficient to modulate MHC-II antigen presentation,
BCBL-1 control and vIRF3-expressing BCBL-1 cells were cocul-
tured with MHC-II-matched-allele (DQ6)-restricted LAP/LRS
LANA-specific CD4 T cells, and T cell recognition was measured
from the release of IFN- from the effector cells. The result
showed that the recognition by CD4 T cells was substantially re-
duced with vIRF3-expressing BCBL-1 cells compared with that
achieved with control BCBL-1 cells (Fig. 7C).
Finally, the effect of vIRF3 overexpression on the transcription
of CIITA and MHC-II elements was investigated through QRT-
PCR assays carried out on the total RNA isolated from the NGFR-
sorted population. As shown in Fig. 7D, while the transcription of
most of the MHC-II elements was reduced following the overex-
pression of vIRF3 in BCBL-1 cells, there was no reduction in the
transcription of CIITA by vIRF3.
Therefore, in a PEL background, vIRF3 can reduce the surface
MHC-II DR expression and inhibit MHC-II antigen presentation
through a CIITA-independent mechanism.
FIG 5 vIRF3 inhibits CIITA transcription in a B cell line. (A) Akata-A3 cells transfected with pRTS-CD2-vIRF3 were induced with the indicated concentrations
of DOX and sorted with NGFR-specific magnetic beads. The lysates of purified NGFR cells were analyzed by SDS-PAGE alongside lysates from uninduced
vIRF3-expressing Akata-A3 cells and JSC-1 cells. The samples were immunoblotted with antibodies specific for vIRF3 or calregulin as a loading control. (B)
Akata-A3 cells transfected with pRTS-CD2-vIRF3 or pRTS-CD2-control were induced with 2 ng/ml of DOX, and viable cells were stained with PE-conjugated
anti-DR for analysis by flow cytometry. Histograms show the surface MHC-II DR expression on GFP	 cells and GFP cells in both cultures. (C) Akata-A3 cells
transfected with pRTS-CD2-vIRF3 or pRTS-CD2-control were induced with 2 ng/ml of DOX and sorted with NGFR magnetic beads. The lysates of purified
NGFR cells were analyzed by SDS-PAGE and immunoblotting with antibodies specific for vIRF3, DR, DR, DM, MHC-I (HC10), or calregulin as a loading
control. (D) Relative levels of CIITA, DRA, DRB, DQA, DPA, DMA, DOA, CD74, and HLA-A transcripts in total RNA isolated from transduced and sorted cells
normalized to the levels of the GAPDH transcripts measured were measured by QRT-PCR assay. The error bars represent the standard deviations of triplicate
reactions.
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DISCUSSION
Consistent with a recent report that vIRF3 has the potential to
inhibit the transcription of CIITA and the subsequent expression
of MHC-II genes (17), we have now shown, using antigen-specific
recognition by CD4 T cells, that vIRF3 can modulate the MHC-II
antigen presentation function in melanoma cells, B cells, and PEL
cells. These functional assays revealed a level of complexity that
was not evident from the previous biochemical observations.
Thus, while we confirmed that vIRF3 can indeed downregulate
MHC-II DR expression, the kinetics of this effect were slow and
were preceded by a substantial impairment in presentation of an-
tigen to CD4 effector T cells. Furthermore, while CIITA might
contribute to the downregulation of MHC-II molecules under
some circumstances, our combined data from different cell lines
and particularly PEL lines show that the modulation of MHC-II
antigen presentation by vIRF3 may be mediated predominantly
through CIITA-independent mechanisms.
CIITA is a master regulator of the expression of MHC-II ele-
ments, including HLA-DR, HLA-DQ, HLA-DP, HLA-DM, HLA-
DO, and invariant chain/CD74. It is a transcriptional coactivator
that lacks an intrinsic DNA-binding function. It enhances the
transcription of MHC-II genes through interaction with tran-
scription regulatory proteins, forming a stable enhanceosome that
can bind to the regulatory module of MHC-II promoters (26, 27).
CIITA appears to be a vulnerable target for viral modulation of
MHC-II gene expression (17, 28). Li et al. demonstrated that the
EBV-encoded immediate early protein BZLF1, which is the mas-
FIG 6 vIRF3 can modulate MHC-II antigen presentation in LCLs. (A) HLA-
DQ6- and HLA-A2-typing LCLs were transduced with pLZRS-vIRF3-IRES-
NGFR or with control pLZRS-B81-IRES-NGFR retrovirus and sorted with
NGFR magnetic beads. The lysates of the purified NGFR cells from both
transductions, along with those of the KSHV control PEL line JSC-1, were
analyzed by SDS-PAGE and immunoblotting with antibodies specific for
vIRF3, DR, or calregulin as a loading control. Histograms show the surface
MHC-II DR expression on LCL control cells and vIRF3-expressing LCL cells.
(B) Control LCL cells and vIRF3-expressing LCL cells were pulsed with LANA
protein or a control protein overnight and were then cocultured with LAP/LRS
CD4 effector T cells (DQ6 restricted and specific for LANA-derived peptide)
for a further 18 h before assaying for T cell recognition by IFN--specific
ELISA. The LCL cells pulsed with peptides served as a control. Error bars for
IFN- release in the histograms indicate the standard deviations of triplicate
cultures. (C) The control LCL cells and vIRF3-expressing LCL cells were cocul-
tured with CLG CD8 effector T cells (A2 restricted and specific for EBV
LMP2-derived peptide) and assayed for IFN- by ELISA.
FIG 7 vIRF3 modulates MHC-II antigen presentation in the BCBL-1 PEL line
independently of inhibition of CIITA. BCBL-1 cells were transduced with
pLZRS-vIRF3-IRES-NGFR or control pLZRS-B81-IRES-NGFR retrovirus.
(A) The transduced cells were stained with PE-conjugated anti-DR plus FITC-
conjugated anti-NGFR and analyzed by flow cytometry for surface MHC-II
DR expression on NGFR	 cells and NGFR cells. (B) The transduced cells
were sorted with NGFR-specific magnetic beads. The lysates of purified
NGFR cells from both transductions, along with those of the control JSC-1
PEL line, were analyzed by SDS-PAGE and immunoblotting with antibodies
specific for vIRF3, DR, LANA, or calregulin as a loading control. (C) The
BCBL-1 control and vIRF3-expressing BCBL-1 cells were cocultured with
LAP/LRS CD4 effector T cells (DQ6 restricted and specific for LANA-derived
peptide) for 18 h before assaying for T cell recognition by IFN--specific
ELISA. A DQ6-positive LCL pulsed with target peptides served as a control.
Error bars for IFN- release in the histograms indicate the standard deviations
of triplicate cultures. (D) Relative levels of CIITA, DRA, DRB, DQA, DPA,
DMA, DOA, CD74, and HLA-A transcripts in total RNA isolated from trans-
duced and sorted cells normalized to the levels of the GAPDH transcripts
measured were measured by QRT-PCR assay. The error bars represent the
standard deviations of triplicate reactions.
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ter regulator of the EBV lytic cycle, can bind to the CIITA pro-
moter and strongly inhibit the transcription and constitutive ex-
pression of CIITA molecules (28). MHC-II molecules are
constitutively expressed on professional antigen-presenting cells,
which express CTIIA, but the expression can also be induced on
other cells by IFN- through the induced transcription of CIITA.
In this context, HCMV infection of U373 MG cells reduced the
level of IFN--induced CIITA transcripts by more than 10-fold,
with a concordant inhibition of induced MHC-II DR synthesis
(29). Similarly, varicella-zoster virus infection of human foreskin
fibroblasts can prevent IFN--induced CIITA expression and ex-
pression of MHC-II molecules (30). KSHV vIRF3 can inhibit both
constitutive and IFN--induced CIITA transcription (17), but in
the light of the findings of our present work, it is possible that the
action of vIRF3 on CTIIA might be most important for inhibiting
the IFN--induced CTIIA.
As MHC-II molecules have a long half-life compared to
MHC-I molecules (31), inhibition of CIITA and thus MHC-II
gene transcription would not be expected to have a rapid effect on
preexisting MHC-II protein levels. Indeed, both in a previous
study by Schmidt and colleagues (17) and in the present work, a
relatively small downregulation of MHC-II protein was observed
48 h after expression of vIRF3 vectors. Interestingly, over a longer
time course in the MJS cell line, inhibition of transcription was
observed to be a very effective mechanism to modulate the expres-
sion of MHC-II proteins; after 5 to 7 days of expression of vIRF3,
expression of the MHC-II DR protein on the cell surface was re-
duced by more than 10-fold (Fig. 3B). As vIRF3 is a KSHV latent
protein that is consistently expressed in the KSHV-positive PEL
line (25), we postulate that the effect of vIRF3 on MHC-II tran-
scription, whether it is via CTIIA or not, is a major factor respon-
sible for maintaining the phenotype of little or no MHC-II expres-
sion in these tumors. In our experiments with B cells, expression
of vIRF3 had no effect (Akata-A3) or little effect (BCBL-1) on total
MHC-II DR expression. One possible explanation for this could
be that MHC-II DR is even more stable in B cells than MJS and
epithelial cells, so that downregulation of total MHC-II DR would
require a longer time; it is difficult to test this experimentally, as we
found vIRF3 to be toxic over prolonged periods in these cells.
Another possibility, which is not mutually exclusive, is that tran-
scriptional regulation of MHC-II is not the major mechanism by
which vIRF3 interferes with antigen presentation in B cells.
Three lines of evidence indicate that vIRF3 effects a CIITA-
independent mechanism to modulate MHC-II antigen presenta-
tion. First, vIRF3 mediated significant downregulation of MHC-II
DR in CIITA-expressing MJS cells that ectopically overexpress
CIITA from a retroviral vector (Fig. 4). Second, EBV-transformed
LCLs stably expressing vIRF3 showed a reduced ability to present
MHC-II/peptide to CD4 T cells, even though no inhibition of
CIITA transcripts was detected by QRT-PCR (data not shown).
Finally, ectopic overexpression of vIRF3 in the BCBL-1 PEL line
did not alter the levels of CIITA transcripts but did reduce
MHC-II transcription, expression, and recognition by CD4 T cells
(Fig. 7). This CIITA-independent inhibition of the transcription
of MHC-II elements in BCBL-1 cells by vIRF3 sheds some light on
the nature of the mechanism, pointing to an alternative regulation
of MHC-II element transcription. However, the data obtained
from LCLs (Fig. 6) suggest that this is not the only CIITA-inde-
pendent mechanism, as here vIRF3 inhibited the MHC-II antigen
presentation function in the absence of any effect on MHC-II
expression. The utilization of dual molecular mechanisms im-
pacting antigen presentation is not unique to vIRF3. For example,
EBV-encoded BZLF1 inhibits CIITA transcription (28) but also
downregulates the surface expression of CD74 and T cell recogni-
tion in a CIITA-independent manner (14).
It is important to note from both this study and our previous
work that surface MHC-II expression levels do not necessarily
correlate with the MHC-II antigen presentation function. In one
sense, this is unsurprising, as viral modulation of antigen presen-
tation is known to target multiple points in the processing path-
ways, some of which might qualitatively alter the MHC/peptide
complexes without necessarily affecting the quantity of MHC-II
molecules at the cell surface. Functional T cell assays are exqui-
sitely sensitive to such qualitative changes that are not detected in
routine biochemical assays. In the present study, there was a sub-
stantial reduction in CD4 T cell recognition at 2 days after expres-
sion of vIRF3, when surface MHC-II levels were barely affected.
Although this observation might be less relevant to the latent ex-
pression pattern of vIRF3 in KSHV-positive tumor cells, where the
longer-term effects of CTIIA inhibition may be effective, we spec-
ulate that it could well be important in the early stage of KSHV
infection of nonmalignant cells to prevent their recognition and
elimination by KSHV-specific CD4 T cells.
T-cell responses to KSHV-encoded latent antigens and lytic
antigens have been identified in both healthy immunocompetent
donors and immunocompromised patients (32–37). Although
generally weak, KSHV-specific CD8 T cells responses are more
frequent, diverse, and strong in asymptomatic KSHV-infected pa-
tients than Kaposi’s sarcoma patients (38). Very recently, Sabbah
et al. found that the responses in healthy KSHV-infected donors to
the KSHV latent antigens were most frequently directed to LANA-
derived peptides (16). Interestingly, most of the LANA-specific T
cell clones generated were CD4 lymphocytes. It might therefore be
speculated that in order to establish a persistent infection (and
also to generate malignancies), it is necessary for KSHV-infected
cells to evade not only CD8 responses, for which various mecha-
nisms have been identified (7, 8, 21, 39, 40), but also CD4 T cell
responses.
Generally, effector CD4 T cells can be generated during both
chronic and acute infection with herpesviruses and are important
for controlling the infection through both cytotoxic and cytokine-
dependent mechanisms. Many herpesviruses encode multiple im-
munoevasins which together target MHC-II processing and pre-
sentation pathways. There is now accumulating evidence to
suggest that the same may be true for KSHV. A recent study
showed that KSHV infection of human primary endothelial cells
inhibits IFN--induced expression of the MHC-II molecule at the
transcriptional level via soluble mediators, including cytokines
released from KSHV-infected endothelial cells (41). This is likely
to be a mechanism separate from that identified in the present
study, as we have observed the effects of vIRF3 on T cell recogni-
tion in the absence of effects on MHC-II expression.
Multiple functions have been ascribed to vIRF3. For example,
it binds to IRF5 and inhibits interferon-responsive transcription
(42); it can potently inhibit the transcription induced by overex-
pression of p53 and, consequently, inhibit apoptosis (25); it has
been reported to be associated with the c-myc suppressor, which
in turn stimulates c-myc-mediated transcription and conse-
quently contributes to B cell growth (43); and it can specifically
interact with the hypoxia-inducible factor 1 (HIF-1) alpha sub-
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unit, leading to HIF-1 stabilization and transcriptional activation
(44). Ultimately, vIRF-3 was shown to be indispensable to the
proliferation of PEL cells in culture and has been proposed to be a
predominant factor in the pathogenesis of PEL cells (45). Indeed,
in our study we tried to knock down vIRF3 expression in PEL cells
with small interfering RNA or short hairpin RNA in an attempt to
reverse the immune-modulatory phenotype of vIRF3, but we were
unable to generate a stable line with lower vIRF3 expression (data
not shown). To circumvent this problem, we took advantage of
the fact that some PEL lines contained a small population of cells
with high surface MHC-II expression and lower vIRF3 expression
(Fig. 1). Interestingly, the variations in MHC-II and vIRF3 expres-
sion were dynamic, as when the high- and low-expressing sorted
populations were returned to culture, they reverted to the mean
level of expression within 7 days (data not shown). This phenom-
enon probably reflects the fact that a critical level of vIRF3 expres-
sion is required for continued growth of the cells. However, if the
mechanism of vIRF3 regulation were to be elucidated, it might be
targeted therapeutically in PELs; reduced vIRF3 expression might
both impair their growth and/or survival and also render the tu-
mors susceptible to LANA-specific CD4 effector T cells.
In summary, this study has characterized aspects of the
MHC-II immune modulation function of vIRF3 that extend our
understanding of the roles of this protein in infection of nonma-
lignant target cells in asymptomatic persistence and in the KSHV-
associated malignancy PEL.
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